AKT1 and melanoma: The relative tolerability and promising PK characteristics of the combination in dogs during the short-term repeat dose exposures support further evaluation of effectiveness in canine clinical trials for dogs with naturally occurring melanoma and other cancers with activation of one or more of the RAS/MAPK and PI3K/Akt/mTOR pathways.